Prevalence, determinants and co-morbidities of chronic kidney disease among First Nations adults with diabetes: results from the CIRCLE study

Dyck, Roland F; Naqshbandi Hayward, Mariam; Harris, Stewart B

doi:10.1186/1471-2369-13-57

Table 2 Characteristics of Circle participants by eGFR category and urine albumin (Ua) positivity (+/−) when eGFR = > 60

From: Prevalence, determinants and co-morbidities of chronic kidney disease among First Nations adults with diabetes: results from the CIRCLE study

PARAMETER* (Mean values or %)	eGFR Groups	eGFR = < 90			eGFR 60 - < 90			eGFR = > 60 Total**			eGFR 30 - <60		eGFR <30 (no RRT)		eGFR <15 RRT		All eGFR < 60 = CKD-eGFR <60
	Total	Non-CKD (UA-)	CKD-alb (UA+)	p	Non-CKD (UA-)	CKD-alb (UA+)	p	Non-CKD (UA-)	CKD-alb (UA+)	p	Stage 3 CKD	p vs Non-CKD	Stage 4/5a CKD	p vs Non- CKD	Stage 5b CKD	p vs Non- CKD	Stage 3-5b CKD	p vs Non- CKD
NUMBER	715	147	220	…	95	121	…	242	341	…	105	…	19	…	8	…	132	…
% FEMALE	65.3	68.7	63.6	n/s	71.6	56.2		69.8	61.0	0.017	72.4	n/s	68.4	n/s	12.5	0.002	68.2	n/s
AGE AT AUDIT	55.6	47.6	49.4	n/s	59.6	61.3	n/s	52.3	53.6	n/s	68.1	0.000	62.7	0.001	56.0	n/s	66.6	0.000
age diagnosis	44.3	39.7	39.4	n/s	49.9	48.1	n/s	43.6	42.4	n/s	53.0	0.000	42.2	n/s	35.9	n/s	50.4	0.000
duration diabetes	10.4	7.1	9.3	0.001	8.8	12.3	0.001	7.8	10.3	0.000	14.3	0.000	20.1	0.000	19.1	0.000	15.4	0.000
BMI	33.8	35.6	33.4	n/s	34.8	33.7	n/s	34.7	33.5	n/s	33.3	n/s	33.6	n/s	27.5	0.004	32.9	0.033
% SMOKER	38.7	50	48.5	n/s	30.4	27.3	n/s	42.2	41.1	n/s	23	0.001	27.8	n/s	37.5	n/s	26.2	0.002
BLD PRESSURE
sBP (mm Hg)	132.2	128.2	132.3	0.016	129.4	135.1	0.015	128.7	133.3	0.001	135.6	0.002	137.5	0.018	139.3	n/s	136.1	0.000
dBP (mm Hg)	75.5	76.3	77.3	n/s	75.4	74.9	n/s	75.9	76.4	n/s	72.2	0.002	74.05	n/s	72.8	n/s	72.5	0.002
BLOOD TESTS
A1C (mean %)	8.14	8.05	8.95	0.000	7.18	8.19	0.000	7.72	8.68	0.000	7.57	n/s	7.65	n/s	6.25	0.033	7.5	n/s
TC (mM)	4.52	4.38	4.70	0.006	4.37	4.45	n/s	4.38	4.61	0.008	4.48	n/s	4.84	n/s	4.66	n/s	4.54	n/s
LDL (mM)	2.38	2.34	2.44	n/s	2.33	2.33	n/s	2.33	2.40	n/s	2.39	n/s	2.6	n/s	2.44	n/s	2.43	n/s
HDL (mM)	1.21	1.21	1.25	n/s	1.19	1.18	n/s	1.20	1.22	n/s	1.23	n/s	1.23	n/s	1.04	n/s	1.22	n/s
COMORBIDITIES
All Macrovasc (%)	21.1	11.6	10.5	n/s	23.2	25.6	n/s	16.1	15.8	n/s	38.1	0.000	68.4	0.000	62.50	0.005	43.9	0.000
% periph vasc	3.9	0.7	1.4	n/s	3.2	5.0	n/s	1.7	2.6	n/s	4.8	n/s	31.6	0.000	50.0	0.000	11.4	0.000
% cerebro vasc	5.3	2.7	2.7	n/s	4.2	5.8	n/s	3.3	3.8	n/s	12.4	0.002	15.8	0.037	12.5	n/s	12.9	0.001
% combined heart	16.1	9.5	7.3	n/s	17.9	19.8	n/s	12.8	11.7	n/s	29.5	0.000	52.6	0.000	37.5	n/s	33.3	0.000
All Microvasc (%)	22.4	11.6	23.2	0.003	11.6	25.6	0.007	11.6	24.0	0.000	32.4	0.000	47.4	0.000	87.5	0.000	37.9	0.000
% foot disease	4.6	2.0	5.0	n/s	0.0	2.5	n/s	1.2	4.1	0.034	8.6	0.002	21.1	0.001	37.5	0.000	12.1	0.000
% eye disease	13.8	6.1	13.6	0.015	9.5	15.7	n/s	7.4	14.4	0.006	20.0	0.001	21.1	0.063	85.5	0.000	24.2	0.000
% neuropathy	12.7	6.1	13.2	0.021	7.4	14.0	n/s	6.6	13.5	0.005	17.1	0.003	21.1	0.046	87.5	0.000	22.0	0.000
MEDICATIONS
% Insulin	30.1	18.4	33.2	0.001	21.1	38	0.005	19.4	34.9	0.000	30.5	0.018	57.9	0.000	75	0.001	37.1	0.000
% RAAS agents	75.2	63.3	76.8	0.004	73.7	85.1	0.028	67.4	79.8	0.001	81.9	0.004	63.2	n/s	62.5	n/s	78.0	0.019

* BMI-body mass index, sBP-systolic blood pressure, dBP-diastolic Blood pressure, A1C-glycosylated hemoglobin, TC-total cholesterol, LDL-LDL cholesterol, HDL-HDL cholesterol; periph vasc-peripheral vascular disease; cerebro vasc-cerebral vascular disease; combined heart- coronary artery disease and/or left ventricle hypertrophy and/or congestive heart failure. RAAS agents- containing angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
**Total non-CKD is comparison group for all sub-groups and total with eGFR < 60.

Back to article page

ISSN: 1471-2369

Contact us

Submission enquiries: bmcnephrology@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Nephrology

Contact us